Antipsoriatic Effect of a Topical Formulation for the Treatment of Psoriasis Vulgaris

Inclusion Criteria: * men aged 18 years or older * subjects with mild to moderate psoriasis vulgaris in a chronic stable phase * subject with up to three stable plaques with an area sufficient for five treatment fields * Plaques to be treated should have a comparable thickness of the Echo Lucent Band of at least 200 µm Exclusion Criteria: * Subjects with guttate psoriasis, punctate psoriasis, erythrodermic psoriasis, psoriatic arthropathy and pustular psoriasis * Local treatment with antipsoriatics in the 4 weeks preceding and/or during the trial, and any topical antipsoriatic treatment on the plaques to be treated in this trial in the 8 weeks before first treatment and/or during the trial * Systemic treatment with antipsoriatics e.g. corticosteroids, cytostatics, retinoids in the three months before first treatment and during the trial; * Treatment with systemic medications or medications acting locally which might have countered or influenced the trial aim * Contraindications according to summary of product characteristics of Daivonex® Ointment; * UV-therapy within four weeks before first treatment and during the trial * Symptoms of a clinically significant illness that may influence the outcome of the trial in the four weeks before baseline visit and during the trial * Any history of cardiovascular disease * Any evidence of ECG abnormality on screening ECG * Close affiliation with the Investigator (e.g. a close relative) or persons working at bioskin GmbH or subject is an employee of the Sponsor; * Subject is institutionalized because of legal or regulatory order.